Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database
{{output}}
Background: Bevacizumab, an anti-vascular endothelial growth factor agent initially approved for cancer treatment, is widely used off-label in retinal vascular diseases; however, this use may carry safety risks, particularly when... ...
